Gene · 6595
Papers3,459
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,459
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Study on the changes of extracellular matrix morphology and components in COPD animal model by using lung decellularized scaffold. | FASEB J | 2025 | 40150895 | PubTator, text mining | PubMed |
| Tyr1497 in the BRG1 Bromodomain of the SWI/SNF Complex is Critical for the Binding and Function of a Selective BRG1 Inhibitor. | J Cell Mol Med | 2025 | 40133216 | PubTator, text mining | PubMed |
| Novel 1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer. | ACS Med Chem Lett | 2025 | 40104805 | PubTator, text mining | PubMed |
Loss of SWI/SNF complex expression (SMARCA4, SMARCA2, SMARCB1, ARID1A) is associated with dMMR in primary adenocarcinoma of jejunum and ileum: A clinicopathological and molecular analysis based on the Chinese population. | Pathol Res Pract | 2025 | 40101550 | PubTator, text mining | PubMed |
| Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. | Blood Cancer J | 2025 | 40089460 | PubTator, text mining | PubMed |
| Mesenteric SMARCA2-Deficient Yet SMARCA4-Preserved Aggressive Undifferentiated Tumor: A Case Report. | Surg Case Rep | 2025 | 40012963 | PubTator, text mining | PubMed |
| Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers. | Trends Cancer | 2025 | 39971696 | PubTator, text mining | PubMed |
| Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type. | iScience | 2025 | 39906560 | PubTator, text mining | PubMed |
| MAAT: a new nonparametric Bayesian framework for incorporating multiple functional annotations in transcriptome-wide association studies. | Genome Biol | 2025 | 39905509 | PubTator, text mining | PubMed |
| SMARCA4 deficiency in small cell lung cancer: A case report and narrative review of the literature. | Biomol Biomed | 2025 | 39888726 | PubTator, text mining | PubMed |
| SMARCA2 protein: Structure, function and perspectives of drug design. | Eur J Med Chem | 2025 | 39879937 | PubTator, text mining | PubMed |
| Prognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma. | Histopathology | 2025 | 39811899 | PubTator, text mining | PubMed |
| Probing Biomolecular Interactions with Paramagnetic Nuclear Magnetic Resonance Spectroscopy. | Chembiochem | 2025 | 39803829 | PubTator, text mining | PubMed |
| H19/miR-484 axis serves as a candidate biomarker correlated with autism spectrum disorder. | Int J Dev Neurosci | 2025 | 39749992 | PubTator, text mining | PubMed |
| Long non-coding RNAs direct the SWI/SNF complex to cell type-specific enhancers. | Nat Commun | 2025 | 39747144 | PubTator, text mining | PubMed |
| Discovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers. | J Med Chem | 2025 | 39745073 | PubTator, text mining | PubMed |
| Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders. | J Med Chem | 2025 | 39745064 | PubTator, text mining | PubMed |
| Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma. | Pathol Res Pract | 2025 | 39693721 | PubTator, text mining | PubMed |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | 39625239 | PubTator, text mining | PubMed |
| Genetic Etiology Investigation in Treatment-Resistant Nocturnal Enuresis Children: A descriptive study. | Urol J | 2025 | 39616448 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6595/papers?page=9